Published in Clinical Trials Week, November 29th, 2004
The company also announced that CR002, a fully human monoclonal antibody, is being developed for the treatment of IgA nephropathy and will begin a phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male volunteers.
"We are very pleased to transition CG53135 into phase II and bring CR002 into a phase I program. CuraGen...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.